

PRODUCT INFORMATION



EPZ004777 (formate)

Item No. 16173

Formal Name: 7-[5-deoxy-5-[[[3-[[[4-(1,1-dimethylethyl)phenyl]amino]carbonyl]amino]propyl](1-methylethyl)amino]-β-D-ribofuranosyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine, monoformic acid

MF: C₂₈H₄₁N₇O₄ • CH₂O₂

FW: 585.7


Purity: ≥98%

UV/Vis.: λ_{max}: 242, 271 nm

Supplied as: A crystalline solid

Storage: -20°C

Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

EPZ004777 (formate) is supplied as a crystalline solid. A stock solution may be made by dissolving the EPZ004777 (formate) in the solvent of choice, which should be purged with an inert gas. EPZ004777 (formate) is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide. The solubility of EPZ004777 (formate) in these solvents is approximately 10 mg/ml.

EPZ004777 (formate) is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, EPZ004777 (formate) should first be dissolved in ethanol and then diluted with the aqueous buffer of choice. EPZ004777 (formate) has a solubility of approximately 0.5 mg/ml in a 1:1 solution of ethanol:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

EPZ004777 is a potent inhibitor of DOT1L (IC₅₀ = 400 pM) that selectively kills mixed lineage leukemia (MLL) cells *in vitro* and prolongs survival in an MLL xenograft mouse model.¹⁻⁴ It displays >1,000-fold selectivity for DOT1L relative to a panel of histone methyltransferases.¹ DOT1L inhibition by EPZ004777 has also been shown to accelerate the reprogramming of somatic cells into induced pluripotent stem cells.⁵

References

1. Daigle, S.R., Olhava, E.J., Therkelsen, C.A., *et al.* Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. *Cancer Cell*. **20**(1), 53-65 (2011).
2. Chen, L., Deshpande, A.J., Banka, D., *et al.* Abrogation of MLL-AF10 and CALM-AF10-mediated transformation through genetic inactivation or pharmacological inhibition of the H3K79 methyltransferase Dot1l. *Leukemia* **27**(4), 813-822 (2013).
3. Deshpande, A.J., Chen, L., Fazio, M., *et al.* Leukemic transformation by the MLL-AF6 fusion oncogene requires the H3K79 methyltransferase Dot1l. *Blood* **121**(13), 2533-2541 (2013).
4. Yu, W., Chory, E.J., Wernimont, A.K., *et al.* Catalytic site remodelling of the DOT1L methyltransferase by selective inhibitors. *Nat. Commun.* **3**, 1288 (2012).
5. Ye, J., Ge, J., Zhang, X., *et al.* Pluripotent stem cells induced from mouse neural stem cells and small intestinal epithelial cells by small molecule compounds. *Cell Res.* **26**(1), 34-45 (2016).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/07/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD

ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM